臨床検査51巻4号

2007年04月発行

今月の主題 悪性リンパ腫 各論

悪性リンパ腫の治療戦略とそのEBM―非ホジキンリンパ腫 (１) B細胞性

著者： 岡本真一郎¹

所属機関： ¹慶應義塾大学医学部血液内科

ページ範囲：P.409 - P.415

　B細胞性非ホジキンリンパ腫の中で頻度が高い疾患は，び慢性大細胞型リンパ腫(diffuse large cell lymphoma；DLCL)と濾胞性リンパ腫(follicular lymphoma；FL)である．DLCLでは標準的化学療法(CHOP療法)によって根治が期待できるが，進行病期の治癒率は30～40%と満足できる成績ではない．FLにおいては，化学療法が奏効するものの，根治あるいは生存期間の有意な改善を期待することはできず，症状が悪化するまで経過観察をするといった消極的な立場が主流を占めてきた．しかし最近，rituximabなどの抗体製剤の開発や新たな造血幹細胞移植法の開発によって，両者の予後は大きく改善した．〔臨床検査　51：409-415，2007〕

参考文献

１) Fisher RI, Gaynor ER, Dahlberg S, et al：Comparison of a standard regimen(CHOP)with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med　328：1002-1006, 1993

２) Coiffier B, Lepage E, Briere J, et al：CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med　346：235-242, 2002

３) Habermann TM, Weller EA, Morrison VA, et al：Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol　24：3121-3127, 2006

４) Pfreundschuh M, Kloess M, Zenalova S, et al：Six vs. eight cycle of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma(DLBCL)：Results of the completed RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group(DSHNHL). Blood　108：64a, 2006

５) Pfreundschuh M, Trumer L, Osterborg A, et al：CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma：a randomized study controlled trial by the MabThera International Trial(MINT)Group. Lancet Oncol　7：379-391, 2006

６) Marcus RE, Solal-Celigny P, Imrie K, et al：MabThera(rituximab)plus cyclophosphamide, vincristine and prednisone(CVP)chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin's lymphoma(NHL). Blood　108：146a, 2006

７) Buske C, Kneba M, Lengfelder E, et al：Front-line chemotherapy(R-CHOP)significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma―Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group(GLSG). Blood　108：146a, 2006

８) Hiddemann W, Kneba M, Dreyling M, et al：Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and predinisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone：results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood　106：3725-3732, 2005

９) Press OS, Unger JU, Braziel RM, et al：Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma：five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol　24：4143-4149, 2006

10) Hainsworth JD, Litchy S, Morrissey LH, et al：Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma：a phase II trial of the minnie pearl cancer research network. J Clin Oncol　23：1500-1506, 2005

11) van Oers MH, Klasa R, Marcus RE, et al：Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction：results of a prospective randomized phase 3 intergroup trial. Blood　108：3295-3301, 2006

12) Pfreundschuh M, Schubert J, Schmitz N, et al：Treatment of diffuse large B-dell lymphoma. Hematology(EHA Educational Program)　2：154-160, 2006

13) Philip T, Guglielmi C, Hagenbeek A, et al：Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med　333：1540-1545, 1995

14) Schouten HC, Qian W, Kvaloy S, et al：High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’ s lymphoma：results from the randomized European CUP trial. J Clin Oncol　21：3918-3927, 2003

15) Deconinck E, Foussard C, Milpied N, et al：High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma：a randomized multicenter study by GOELAMS. Blood　105：3817-3823, 2005

16) Nademanee AP, Krishnan A, Nicole T, et al：90Y-ibritsumomab tiuxetan(Zevalin)in combination with high-dose therapy(HDT)followed by autologous stem cell transplant(ASCT)may improve survival in patients with poor-risk follicular lymphoma(FL)and diffuse large B-cell lymphoma(DLBCL)：Results of a retrospective comparative analysis. Blood　108：102a, 2006

17) Van Besien K, Loberiza FR Jr, Bajorunaite R, et al：Comparison of autologous and allogeneic hematopoietic stem cell transplantation follicular lymphoma. Blood　102：3521-3529, 2003

18) Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al：An EBMT registry matched study of allogeneic stem cell transplants for lymphoma：allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant　31：667-678, 2003

19) Khouri IF, Saliba RM, Giralt SA, et al：Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma：low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood　98：3595-3599, 2004

20) Kusumi E, Kami M, Kanda Y, et al：Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma：a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant　36：205-213, 2005